#Vienna #Austria #diabetes #SIBIONICS #EASD2025

SiBionics at EASD 2025: Innovations in Diabetes Management

At the 61st Annual Meeting of the European Association for the Study of Diabetes (EASD) held in Vienna, SiBionics unveiled its integrated diabetes management solution, comprising the Continuous Glucose Monitoring (CGM) system and the Continuous Ketone Monitoring (CKM) device. This innovative approach received significant acclaim from renowned researchers and experts from across the globe.

The symposium titled "CGM + CKM for Better Diabetes Management" brought together international experts who shared the latest scientific data, sparking lively discussions and wide approval regarding the potential of SiBionics’ technology to transform diabetes care. With diabetes increasingly becoming a global health concern, the technologies presented are positioned to address this challenge effectively.

Among the highlights was the co-chairing of the conference by Professor Linong Ji from Beijing University People's Hospital and Professor Stefano Genovese from Italy, who facilitated engaging dialogues on the advancements in diabetes management. Additionally, prominent researchers such as Professor Andrej Janež from Slovenia, Professor Nina Jendrike from Germany, and Dr. Yifei Mo from China presented their cutting-edge research findings during the event, emphasizing the significance of collaboration in advancements within the field.

On the exhibition floor, SiBionics' next-generation devices, including the CGM GS3 and CKM KS3, became focal points as attendees flocked to learn more about these innovative technologies. Their advanced capabilities and clinical relevance sparked considerable interest, leading to many engaging discussions with the SiBionics team about how these devices can enhance real-world diabetes management.

Notably, a feasibility study has confirmed that the CGM GS3 meets and exceeds the standards set for the iCGM across numerous key performance indicators. It has been recognized for its high accuracy and clinical reliability, demonstrating exceptional performance particularly in low-glucose ranges. This surpasses the iCGM requirements, enhancing its role in clinical decision-making and self-management for patients, confirming its utility in the practical healthcare environment.

As a leader in continuous monitoring technologies and the only company worldwide marketing the CKM, SiBionics has showcased its strong research and development capabilities alongside a pioneering vision in diabetes care. The company's commitment to innovation is evident in its plans to further develop its CXM portfolio, continually striving to deliver accurate and top-quality solutions that improve health outcomes for individuals living with diabetes globally.

About SiBionics

Founded in 2015, SiBionics is at the forefront of medical device technology based in Shenzhen and Irvine, specializing in biosensor innovation. The company combines continuous monitoring technology, intelligent algorithms, and user-friendly software to enhance health management. With over 500 employees, including 25% in research and development, SiBionics is dedicated to advancing personalized and data-driven healthcare solutions for diabetes.

For more information, SiBionics can be reached via email at [email protected] and their latest updates can be followed through their official media channels.